RxDoctor Payments Data

Susan Baker

Family · Rocky Mount, NCNPI 1154683217

Payments from drug & device makers

$372in general payments, 2019–2025

Across 17 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$119
  • Corcept Therapeutics$72
  • Amgen$43
  • Organon$40
  • Lilly USA, LLC$31
  • Abbott$24
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$372 in reported general payments places this provider in the 50th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$169
Medicare patients
17
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide121$157,272
EliquisApixaban80$85,493
RybelsusSemaglutide28$41,724
MounjaroTirzepatide38$38,248
FarxigaDapagliflozin Propanediol27$31,662
XareltoRivaroxaban27$31,502
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$26,964
JardianceEmpagliflozin11$19,725
TradjentaLinagliptin15$18,113
LinzessLinaclotide17$12,007
Breo ElliptaFluticasone/Vilanterol16$8,840
Tresiba Flextouch U-100Insulin Degludec16$8,514
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$7,823
SymbicortBudesonide/Formoterol Fumarate18$6,622
Humalog Kwikpen U-100Insulin Lispro12$4,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$119$198,996149 claims
Lilly USA, LLCMounjaro$31$38,24838 claims
Johnson & JohnsonXarelto$24$31,50227 claims
AbbVieLinzess$19$12,00717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,522 family providers in North Carolina.

Other family in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →